DOCSLIB.ORG

Kalbe Farma (KLBF

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kalbe Farma (KLBF Company Update Indonesia 11 November 2019 Healthcare | Pharmaceuticals Kalbe Farma (KLBF IJ) Buy (Maintained) Ground Checks: Investment In The Future; BUY Target Price (Return) IDR2,000 (+25%) Price: IDR1,595 Market Cap: USD5,309bn Avg Daily Turnover (IDR/USD) 49bn/3.5m Maintain BUY and IDR2,000 TP, 25% upside plus c.2% yield. We recently Analysts visited the Kalbio Global Medika (KGM) production facility in Cikarang, West Java. KGM, KLBF’s subsidiary, specialises in biosimilar products, in Jessica Pratiwi partnership with South Korean biotechnology R&D company, Genexine Inc. +6221 5093 9845 The facility has a land area of 11,000 sqm and 195 employees. The site visit [email protected] was hosted by Daniel Iskandar Wirawan (site head) and Fahrizal Nugraha (QC manager) from KGM, and Megawati Purnama and Marcella Cloudia (KLBF investor relations team). Michael W Setjoadi Higher biosimilar sales to support declining pharma margins. Competition +6221 5093 9844 in the biosimilar market is not as strong as in generic drugs given the high [email protected] development costs and production complexity (c.2 months/batch). The two local competitors are Combiphar Dong-A and Daewoong Infion. EBIT margin Share Performance (%) in this segment is also much more attractive at 23-25% vs 8-10% for unbranded YTD 1m 3m 6m 12m generics. Absolute 4.3 (2.8) 10.8 5.7 14.0 Currently, 90% of KLBF’s biosimilars, mainly the Hemapo drug (c.3,000 Relative 4.7 (5.5) 11.5 7.8 10.2 units/year), are for National Social Health Insurance (JKN) patients. The 52-wk Price low/high (IDR) 1,260 – 1,690 products are still fully imported from Kalbe Farma’s partner in China (Shandong Kexing Bioproducts) as local production will only start next year. Including Kalbe Farma – IDR oncology drugs, biosimilars contribute c.7-8% of total pharma sales and 2% of IDR the topline, implying c.15% production capacity. KLBF also plans to export 2,000 these products to Myanmar, Cambodia and Africa. Two biosimilars commercially ready by next year, three more in pipeline. 1,800 Two products will be locally produced by 2020: Leucogen (GCSF) for cancer 1,600 treatment post chemotherapy, and Hemapo (erythropoietin, or EPO) for post- 1,595 haemodialysis treatment. Still in the pipeline are Epoeitin (long acting EPO), 1,400 insulin pen cartridges, and monoclonal antibody (mAB) products. New products can take up to 1.5-2 years to produce, due to the complexity of biomedical 1,200 technology transfer, but are potentially less costly than the original biological 1,000 medicine. These five products should increase production capacity utilisation Jul-14 Jul-15 Jul-16 Jul-17 Jul-18 Jul-19 Jan-15 Jan-16 Jan-17 Jan-18 Jan-19 Oct-14 Oct-15 Oct-16 Oct-17 Oct-18 Oct-19 Apr-15 Apr-16 Apr-17 Apr-18 to 40%. Apr-19 What are biosimilars and how big is the potential? A biosimilar is a similar Source: RHB, Bloomberg; Note: As at 7 Nov 2019 version of another already approved biological medicine, both made using living organisms. A biosimilar can only be approved after the patent of the original biological medicine has expired. The process flow (Figure 7) is slightly different from normal chemical medicines, with additional biotech processes. The finished products are filled in syringes, cartridges and vials. According to Results Healthcare, the market reached USD4.4bn in annual sales in 2017, or c.4% of the total biopharmaceuticals market. The biosimilar market is on a growth trajectory, estimated to reach USD25bn by 2023 at a CAGR of 34%. Implications and downside risk. We continue to like KLBF for its value-added products and differentiation initiatives. Private hospitals could potentially use biosimilars as credibility should gradually pick up. Along with personalised medication, biosimilars could be extended to preventive testing using DNA – similar to Prodia’s (PRDA IJ, NR) genetic testing services. Downside risks including development risk and high capital intensity. Forecasts and Valuation Dec-17 Dec-18 Dec-19F Dec-20F Dec-21F Total turnover (IDRbn) 20,182 21,074 22,813 24,836 26,969 Reported net profit (IDRbn) 2,404 2,462 2,632 2,867 3,161 Net profit growth (%) 4.5 2.4 6.9 8.9 10.2 EPS (IDR) 51 53 56 61 67 DPS (IDR) 22 25 26 28 31 P/E (x) 30.9 30.2 28.2 25.9 23.5 P/B (x) 5.6 5.1 4.7 4.2 3.9 Dividend Yield (%) 1.4 1.6 1.7 1.8 1.9 EV/EBITDA (x) 19.9 19.3 18.1 16.6 15.2 ROAE (%) 19.1 17.7 17.2 17.1 17.2 Net gearing (%) net cash net cash net cash net cash net cash Source: RHB, Bloomberg; Note: As at 7 Nov 2019 See important disclosures at the end of this report 1 Kalbe Farma Indonesia Company Update 11 November 2019 Healthcare | Pharmaceuticals Financial Exhibits Asia Indonesia Financial Summary 2017 2018 2019F 2020F 2021F Healthcare Recurring EPS (IDR) 51 53 56.2 61 67 Specialty Pharma DPS (IDR) 22 25 26.3 28 31 BVPS (IDR) 283 311 340.9 374 411 Major shareholders (%) ROE (%) 19 18 17 17 17 Gira Sole Prima 10.2 Santa Seha Sanadi 9.7 Valuation Metrics 2017 2018 2019F 2020F 2021F Diptanala Bahana 9.5 Recurring P/E (x) 30.9 30.2 28.2 25.9 23.5 P/B (x) 5.6 5.1 4.7 4.2 3.9 Valuation basis FCF yield (%) 1.4 2.2 1.9 2.8 3.5 Our 12-month TP of IDR2,000 is based on a 10-year Dividend yield (%) 1.4 1.6 1.7 1.8 1.9 DCF (WACC: 8.9%, terminal growth: 5%). This implies 32x FY20F P/E. EV/EBITDA (x) 19.9 19.3 18.1 16.6 15.2 EV/EBIT (x) 22.7 22.0 20.6 18.9 17.2 Key drivers i. Stable USD/IDR outlook; Income Statement (IDRbn) 2017 2018 2019F 2020F 2021F ii. Better e-catalogue pricing management; Total turnover 20,182 21,074 22,813 24,836 26,969 iii. Higher contribution from biosimilar sales. Gross profit 9,812 9,848 10,600 11,541 12,544 3,662 3,777 4,029 4,407 4,818 Key risks EBITDA (adj.) Depreciation and amortisation 449 463 490 533 579 i. USD appreciation vs IDR; 3,214 3,314 3,539 3,874 4,238 ii. Unfavourable regulations; Operating profit iii. Lower-than-expected consumer purchasing Net interest 99 95 100 83 113 power. Pre-tax profit 3,241 3,351 3,579 3,894 4,288 Taxation (788) (838) (895) (974) (1,072) Company Profile Minority interest 50 51 52 53 55 KLBF produces and develops pharmaceutical products. Net profit 2,404 2,462 2,632 2,867 3,161 The company’s product offerings include medicine, capsules, syrup, and medicines for eye care, animal health, and nutritional uses. It serves patients in Cash Flow (IDRbn) 2017 2018 2019F 2020F 2021F Indonesia. Change in working capital (696) (98) (533) (435) (194) Cash flow from operations 2,064 2,704 2,458 2,823 3,391 (1,143) (1,250) (1,233) (943) (995) Capex Cash flow from investing activities (1,275) (1,360) (1,369) (1,068) (1,129) Dividends paid (1,031) (1,170) (1,231) (1,316) (1,434) Cash flow from financing activities (900) (1,094) (1,190) (1,316) (1,341) Cash at beginning of period 2,896 2,785 3,035 2,934 3,373 Net change in cash (111) 250 (101) 439 921 Ending balance cash 2,785 3,035 2,934 3,373 4,294 Balance Sheet (IDRbn) 2017 2018 2019F 2020F 2021F Total cash and cash equivalents 2,785 3,035 2,934 3,373 4,294 Tangible fixed assets 5,343 6,253 7,127 7,680 8,251 Total assets 16,616 18,147 19,743 21,504 23,588 Short-term debt 169 189 173 133 140 Total long-term debt 146 163 149 115 121 Total liabilities 2,722 2,918 3,070 3,235 3,546 Total equity 13,281 14,575 15,977 17,530 19,260 Minority interests 613 654 696 738 782 Total liabilities and equity 16,616 18,147 19,743 21,504 23,588 Key Metrics 2017 2018 2019F 2020F 2021F Revenue growth (%) 4.2 4.4 8.3 8.9 8.6 Recurrent EPS growth (%) 4.5 2.4 6.9 8.9 10.2 Gross margin (%) 48.6 46.7 46.5 46.5 46.5 EBITDA margin (%) 18.1 17.9 17.7 17.7 17.9 Net profit margin (%) 11.9 11.7 11.5 11.5 11.7 Dividend payout ratio (%) 44.8 48.7 50.0 50.0 50.0 Capex/sales (%) 5.7 5.9 5.4 3.8 3.7 Interest cover (x) 88.3 76.2 75.2 75.6 76.2 Cash conversion cycle (days) 136.3 136.3 137.4 135.7 129.9 Net gearing (%) nc nc nc nc nc Source: Company data, RHB See important disclosures at the end of this report 2 Kalbe Farma Indonesia Company Update 11 November 2019 Healthcare | Pharmaceuticals Figure 1: KLBF’s 9M19 revenue breakdown by segment Figure 2: KLBF’s pharmaceuticals segment breakdown 100% Pharmaceutical; 90% 23.3% 28.9% 27.8% 27.0% 28.0% Distribution & 80% Logistics ; 31.5% 70% 15.1% 16.9% 19.0% 60% 21.0% 50% 40% 30% 56.0% 55.3% 54.0% 51.0% Consumer Health; 20% 16.4% 10% 0% 9M16 (M17 9M18 9M19 Nutritionals; Branded Generics Unbranded Generics Licensed Products 28.8% Source: RHB, Company data Source: RHB, Company data Figure 3: KGM head office in Central Cikarang, Bekasi, West Figure 4: Short presentation by KGM site head Daniel Java, with land area of 11,000 sqm Iskandar, followed by Q&A Source: RHB Source: RHB Figure 5: Comparison between small molecules (chemical-based) medicine vs biologics-based medicines Source: Results Healthcare website See important disclosures at the end of this report 3 Kalbe Farma Indonesia Company Update 11 November 2019 Healthcare | Pharmaceuticals Figure 6: Global biosimilar market size Figure 7: Biosimilar process flow Biotechnology Process Upstream Formulation Cell Culture: Mixing - Roller Bottle - Bioreactor Downstream Filling and Packaging Purification: - Filling - Ultrafiltration - Syringes inspection - Diafiltration - Blistering - Chromatography - Secondary - Bioreactor packaging API Bulk Finished Products Source: Results Healthcare website Source: RHB, Company data Figure 8: Bioreactor Figure 9: Chromatography system Source: RHB Source: RHB Figure 10: Hemapo product, priced at IDR160,000/unit Figure 11: Insulin serum and pen Source: RHB Source: RHB See important disclosures at
Load more

Recommended publications
  • Pasar Farmasi Indonesia
    Company Update Audited FY December 2013 March 2014 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2013 audited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company.
    [Show full text]
  • Pasar Farmasi Indonesia
    Not all collagen is the same, it’s time to choose the right one Company Update Unaudited YTD September 2014 October 2014 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2014 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.
    [Show full text]
  • PT Kalbe Farma Tbk. Dan Entitas Anaknya/And Its Subsidiaries
    PT Kalbe Farma Tbk. dan Entitas Anaknya/ and its Subsidiaries Laporan keuangan konsolidasian tanggal 30 Juni 2019 dan untuk periode yang berakhir pada tanggal tersebut (Belum Diaudit)/ Consolidated financial statements as of June 30, 2019 and for the period then ended (Unaudited) The original consolidated financial statements included herein are in the Indonesian language. PT KALBE FARMA Tbk. DAN ENTITAS ANAK NYA PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES LAPORAN KEUANGAN KONSOLIDASIAN CONSOLIDATED FINANCIAL STATEMENTS TANGGAL 30 JUNI 2019 DAN AS OF JUNE 30, 2019 AND UNTUK PERIODE YANG BERAKHIR PADA FOR THE PERIOD THEN ENDED (UNAUDITED) TANGGAL TERSEBUT (BELUM DIAUDIT) Daftar Isi Table of Contents Halaman/ Page Laporan Posisi Keuangan Konsolidasian ......................... 1-3 ............ Consolidated Statement of Financial Position Laporan Laba Rugi dan Penghasilan Consolidated Statement of Profit or Loss Komprehensif Lain Konsolidasian ............................. 4-5 ..................... and Other Comprehensive Income Laporan Perubahan Ekuitas Konsolidasian ..................... 6 ........... Consolidated Statement of Changes in Equity Laporan Arus Kas Konsolidasian ..................................... 7-8 ..................... Consolidated Statement of Cash Flows Catatan Atas Laporan Keuangan Konsolidasian .............. 9-139 ....... Notes to the Consolidated Financial Statements *************************** g PT KALBE FARMA Tbk. DAN ENTITAS ANAKNYA PT KALBE FARMA Tbk. AND ITS SUBSIDIARIES LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED
    [Show full text]
  • Company Performance Company Performance
    Company Performance YTD September 2008 Contents Part 1 Kalbe at a Glance Part 2 Pharmaceutical Industry Overview Part 3 Business Overview A. Prescription Pharmaceuticals B. Nutritionals C. Consumer Health D. Distribution and Packaging Part 4 Operational Overview Part 5 Growth Drivers Part 6 Financial Overview Part 7 Recent Activities PtPart 8 FtFuture OtlkOutlook 2 Part 1 Kalbe at a Glance 3 Comppyggany Highlights Largest Publicly-Listed ♦ More than 42-year old pharmaceutical company with long track record of profitable growth. Pharmaceutical ♦ After the merger with PT Dankos Laboratories Tbk. and PT Enseval effective on December 16, Company in Southeast 2005, Kalbe has become the largest publicly-listed pharmaceutical company in Southeast Asia with approximately US$ 1 billion market capitalization in the past year. Asia 3 ♦ Lttltif2Large target population of 235 million in In dones ia, an d 570 million in Sou theas t As ia. Substantial Market ♦ OTC and prescription pharma in the Indonesian and Southeast Asian markets expected to grow Opportunity annually at 10% and 13% respectively over the next several years. ♦ The market leader in Indonesian prescription pharma market with 13% market share as well as a Market Leading leader in consumer health market with 16% OTC market share, 9% share in nutrition market and Positions in Indonesia 30% in energy drink market for the first semester in year 2008. ♦ Unrivaled health distribution network which directlyyy and indirectly covers more than 1 million outlets. Strong, Diversified, ♦ Consumer health portfolio which includes 13 market leading OTC brands in 7 main therapeutic categories, the market leading brand in pregnant nutrition and clinical foods, and the leading energy High Growth Product drink in Indonesia.
    [Show full text]
  • PT Kalbe Farma Tbk
    20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT of the FPP manufacturer Part 1 General information Manufacturers details Company information Name of PT. Kalbe Farma Tbk. manufacturer and Delta Silicon Industrial Park address Jl. M. H. Thamrin Blok A3-1, Lippo Cikarang, Bekasi 17550, Indonesia. PO. BOX 371, Bekasi 17037, Indonesia Phone 62-21-89907333 (24 hours) Fax 62-21-8972874 GPS Coordinate ; 6°19’15.4175” South, 107°7’0.1182” East Corporate KALBE Building address of Jl. Let.Jend. Suprapto Kav.4, Central Jakarta 10510 manufacturer PO BOX 3105 JAK, Jakarta , Indonesia Phone 62-21-42873888 – 89 Fax 62-21-42873680 Inspected site Address of As above inspected manufacturing site Unit / block / Production line 8A workshop number WHOPIR PT.Kalbe Farma Tbk, Indonesia 24, 25 and 28 May 2018 This inspection report is the property of the WHO Contact: [email protected] Page 1 of 16 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Manufacturing • CPOB Cairan oral non beta laktam (GMP non beta lactam oral liquid) license number Certificate Number: 4655/CPOB/A/XII/15 License Number: HK.07.IF/V/109/11 License Date: 18 May 2011 Valid until: 31 Dec 2020 • CPOB Kapsul keras non beta laktam (GMP non beta lactam hard capsule) Certificate Number: 4654/CPOB/A/XII/15 License Number: HK.07.IF/V/109/11 License Date: 18 May 2011 Valid
    [Show full text]
  • Evogenix and CSL Partner on Antibodies • Minomic's Business • Japan's Bioventures Today
    www.asiabiotech.com Industry Watch Australia EvoGenix and CSL Partner on Antibodies ntibody therapeutics company, EvoGenix Ltd, had entered a Technology Collaboration agreement with CSL Ltd. EvoGenix will apply its proprietary Atechnologies to antibody products selected by CSL from its pipeline. The collaboration is designed to generate superior antibodies that are more effective as human therapeutics. CSL will have the right to commercialize the products. EvoGenix will receive royalty payments as therapeutics emerging from the collaboration reach the market. Under the terms of the agreement, EvoGenix will receive research payments to carry out work on CSL’s products. Each project carries a success payment for the achievement of project goals, as well as milestone payments as the product advances through the subsequent stages of clinical testing and regulatory approvals. The agreement marks the growing interest of Australian healthcare companies in the dynamic antibody sector, which is seen as the source of many of the future blockbuster drugs. Dr Andrew Cuthbertson, CSL’s Chief Scientific Officer commented, “CSL has identified antibody therapeutics as a focus of its expanding product pipeline. We are delighted to access key technologies which can accelerate development of our antibodies as effective treatments through this collaboration with EvoGenix. “ Dr Rob Crombie, VP for Business Development with EvoGenix, noted “We are looking forward to a highly productive relationship in developing these projects with CSL. As Australia’s leading healthcare company, and with their track record of success in taking biopharmaceuticals to the market, CSL is ideally placed to accelerate antibodies emerging from the collaboration through to becoming successful products.” This is the second major collaboration EvoGenix has made to exploit its proprietary antibody development technologies.
    [Show full text]
  • PT KALBE FARMA Tbk. DAN ANAK PERUSAHAAN PT KALBE FARMA Tbk
    PT Kalbe Farma Tbk. Dan PT Kalbe Farma Tbk. And Anak Perusahaan Subsidiaries Laporan Keuangan Konsolidasi Consolidated Financial Statements (Belum Diaudit) (Unaudited) Untuk Sembilan Bulan Yang Berakhir Pada For The Nine Months Ended Tanggal-tanggal 30 September 2006 Dan 2005 September 30, 2006 And 2005 (Setelah Penggabungan Usaha) (After Merger) (Mata Uang Indonesia) (Indonesian Currency) Meningkatkan Kesehatan untuk Kehidupan yang Lebih Baik To Improve Health for A Better Life The original consolidated financial statements included herein are in Indonesian language. PT KALBE FARMA Tbk. DAN ANAK PERUSAHAAN PT KALBE FARMA Tbk. AND SUBSIDIARIES LAPORAN KEUANGAN KONSOLIDASI CONSOLIDATED FINANCIAL STATEMENTS (BELUM DIAUDIT) (UNAUDITED) SEMBILAN BULAN YANG BERAKHIR PADA NINE MONTHS ENDED TANGGAL-TANGGAL SEPTEMBER 30, 2006 AND 2005 30 SEPTEMBER 2006 DAN 2005 (AFTER MERGER) (SETELAH PENGGABUNGAN USAHA) Daftar Isi Table of Contents Halaman/ Page Neraca Konsolidasi 1-3 Consolidated Balance Sheets Laporan Laba Rugi Konsolidasi 4-5 Consolidated Statements of Income Consolidated Statements of Changes in Laporan Perubahan Ekuitas Konsolidasi 6 Shareholders’ Equity Laporan Arus Kas Konsolidasi 7-8 Consolidated Statements of Cash Flows Catatan atas Laporan Keuangan Konsolidasi 9-87 Notes to the Consolidated Financial Statements *************************** The original consolidated financial statements included herein are in Indonesian language. PT KALBE FARMA Tbk. DAN ANAK PERUSAHAAN PT KALBE FARMA Tbk. AND SUBSIDIARIES NERACA KONSOLIDASI CONSOLIDATED
    [Show full text]
  • Cygenics Asian Healthcare Presence Expanded in Indonesia
    www.asiabiotech.com Industry Watch Australia CyGenics Asian Healthcare Presence Expanded in Indonesia eading tissue and cord blood banking company CyGenics Ltd has announced Indonesia’s leading pharma company, Kalbe Farma, has taken a 49% stake in Lits cord blood banking subsidiary, CordLife Indonesia. CordLife Indonesia will establish new cord blood processing and storage facility to be fully operational by early 2007. CordLife Indonesia will launch expanded marketing and sales of cord blood banking business later this year. This is a further, important step in CyGenics strategy of focusing on its core business of tissue and cord blood banking, and greatly strengthens its presence in a large and important market in the Asian region. The expansion of the Indonesian operations is in line with CyGenics’ focus on revenue generating cord blood banking services and on establishing a sound presence in all major markets in the Asian region. Kalbe Farma is the largest publicly-listed pharmaceutical company in Southeast Asia, with a market capitalisation of approximately US$1.5 billion and US$600 million in annual revenue in 2005. Kalbe Farma has over 12,000 employees, which includes a sales force of 6,000 covering 80% of the Indonesian consumer and hospital health market. Further, it is the dominant supplier to the Indonesian prescription pharmaceutical market. CordLife Indonesia has been in operation since December 2003. The cord blood units have been couriered to Singapore, for processing and storage at the company’s AABB-accredited facility. The volume of business in Indonesia has grown to the extent that the operations now require a cord blood processing and storage facility in the country.
    [Show full text]
  • YS% ,Xld M%Cd;Dka;S%L Iudcjd§ Ckrcfha .Eiü M;%H W;S Úfyi the Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY
    YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha .eiÜ m;%h w;s úfYI The Gazette of the Democratic Socialist Republic of Sri Lanka EXTRAORDINARY wxl 2144$20 - 2019 Tlaf;dan¾ ui 09 jeks nodod - 2019'10'09 No. 2144/20 - WEDNESDAY, OCTOBER 9, 2019 (Published by Authority) PART I : SECTION (I) — GENERAL Government Notifi cations Order No. 01 NATIONAL MEDICINES REGULATORY AUTHORITY ACT, NO. 5 OF 2015 Order under section 60 (2) BY VIRTUE of the powers vested in me by section 60 (2) of the National Medicines Regulatory Authority Act, No. 5 of 2015, I, Prof. Asita De Silva, Chairman of the National Medicines Regulatory Authority, do by this Order, inform the public that the medicines specifi ed in the Schedules here to have been registered with the National Medicines Regulatory Authority. Prof. ASITA DE SILVA Chairman, (For and on behalf of) National Medicines Regulatory Authority Colombo August 8, 2019 1A—PG 4679 - 257 (10/2019) This Gazette Extraordinary can be downloaded from www.documents.gov.lk 2 SCHEDULE - I P ART I:S COLUMN-I COLUMN-II COLUMN- COLUMN-IV COLUMN-V COLUMN- COL- COL- EC III VI UMN-VII UMN-VIII I . (I) - GAZETTE EXTRAORDINARY OF THE DEMOCRATIC SOCIALIST REPUBLIC OF SRI LANKA -09.10.2019 REPUBLICOFSRILANKA SOCIALIST THE DEMOCRATIC OF . (I)-GAZETTEEXTRAORDINARY fldgi (^ Offi cial Name Brand Name Dosage Importer Manufacturer Man- Issue Reg. Form Name Country Date Type 1 BENZALKONIUM CHLORIDE,CETRIMID 0.01%,0.2% DRAPOLENE CREAM GlaxoSmithkiline Glaxo Smithkiline POLAND 24-Mar- Full I & fPoh - YS% ,xld m%cd;dka;s%l iudcjd§ ckrcfha w;s úfYI .eiÜm;%h-2019'10'09
    [Show full text]
  • Equity SNAPSHOT Tuesday, August 24, 2021
    Equity SNAPSHOT Tuesday, August 24, 2021 FROM EQUITY REPORT KEY INDEX KEY INDEX Chg Ytd Vol Chg Ytd Vol Elang Mahkota Teknologi: The E-agle has landed Close Close (EMTK.IJ IDR 2,030 BUY TP. IDR 3,000) (%) (%) (US$ m) (%) (%) (US$ m) EMTK is Indonesia’s own Softbank and Alibaba, supported by its cash Asean - 5 Asean - 5 machine SCMA as the source of funds. EMTK allocate the dividend Indonesia 6.110 1,3 2,2 793 Indonesia 6,134 0.1 (1.0) 318 for tech investments, the most notable is, BUKA being their success Thailand 1.582 1,9 9,2 3.458 Thailand 1,568 (0.1) 0.2 1,454 story whereby the estimated ROI is more than 12x, and from the Philippines 6.592 (0,6) (7,7) 103 Philippines 7,855 (0.3) 5.2 87 recent huge IPO. EMTK recently did an IDR9.3tn NPRI, with some Malaysia 1.522 0,3 (6,4) 447 Malaysia 1,562 (0.5) (7.6) 338 of the proceed invested to Grab Indonesia with the marking of close Singapore 3.088 (0,5) 8,6 1 Singapore 3,173 (0.5) 3.4 908 ties with the Grab ecosystem to further enhance growth. Another Regional Regional group interest is SAME which will be further digitized for value China 3.477 1,5 0,1 108.209 China 2,885 0.3 15.7 28,889 additions. Entrance to digital banking is inevitable we believe due to Hong Kong 25.110 1,0 (7,8) 21.764 Hong Kong 26,391 (0.2) 2.1 9,093 vast potential even just to cater EMTK – Grab customers and Japan 27.770 1,0 1,2 3.516 Japan 23,380 (0.6) 16.8 10,278 partners.
    [Show full text]
  • Indonesia's New Health Regime
    Cover_final_front.pdf 9/21/2010 1:31:39 PM Paper size: 210mm x 270mm Old problems, fresh solutions: Indonesia’s new LONDON health regime 26 Red Lion Square London A report from WC1R 4HQ United Kingdom the Economist Intelligence Unit C Tel: (44.20) 7576 8000 M Fax: (44.20) 7576 8500 Y E-mail: [email protected] CM MY NEW YORK CY 750 Third Avenue CMY 5th Floor K New York, NY 10017, US Tel: (1.212) 554 06000 Fax: (1.212) 586 0248 E-mail: [email protected] HONG KONG 6001, Central Plaza 18 Harbour Road Wanchai Hong Kong Tel: (852) 2585 3888 Fax: (852) 2802 7638 E-mail: [email protected] GENEVA Boulevard des Tranchées 16 1206 Geneva Switzerland Tel: (41) 22 566 2470 Fax: (41) 22 346 93 47 E-mail: [email protected] Sponsored by Old problems, fresh solutions: Indonesia’s new health regime Contents Preface 3 Executive summary 4 1. Introduction 6 2. Inequality: A country divided 9 Low wealth = poor health 9 The need for change 10 3. Innovations in healthcare financing 12 Raising healthcare spending 13 4. Improving health services 15 Prevention preferable to cure 16 5. The innovation imperative 17 Case study 1: A breath of fresh air Frugal innovation saving babies in Vietnam 18 Case study 2: Delinking health from wealth Business model innovation transforming Indian healthcare 19 Case study 3: Dial D for doctor Telemedicine tackling rural doctor shortage in Bangladesh 20 Conclusion 21 © Economist Intelligence Unit 2010 1 Old problems, fresh solutions: Indonesia’s new health regime © 2010 The Economist Intelligence Unit.
    [Show full text]
  • Pasar Farmasi Indonesia
    New solution for sore throat Company Update Unaudited YTD September 2015 October 2015 Forward Looking Statement This presentation has been prepared for informational purposes only by PT Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 30 September 2015 unaudited results of the Company. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors and employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person.
    [Show full text]